Skip to main content

Table 1 Data analysis of included studies

From: Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis

Study N Male Female Age (average) Sources of tumor (N) Volume of MPE (N) Quality of Life End point
Lung/pleura Breast Digestive tract Others
Liu W 2010 [15] 96 51 45 40–70 96 Unavailable KPS RR, DCR, SI, AEs
Mao L 2011 [16] 90 45 45 27–70 81 5 2 2 >1000 ml KPS RR, DCR, SI, AEs
Li G 2011 [17] 60 30 30 41–76 25 20 15 Large (37)
Moderate (23)
KPS RR, DCR, SI, AEs
Ma E 2012 [18] 56 32 24 35–67 56 >1000 ml Unavailable RR, DCR, SI, AEs
Yao Q 2012 [19] 60 42 18 35–78 28 16 4 12 >1000 ml KPS RR, DCR, SI, AEs
Zheng Q 2013 [20] 120 73 47 32–75 78 25 17 >1000 ml KPS RR, DCR, SI, AEs
Kang Y 2013 [21] 90 53 37 18–72 90 >1000 ml KPS RR, DCR, SI, AEs
Wen J 2014 [22] 60 34 26 35–65 (50.5) 45 9 6 Large (13)
Moderate (29)
Small (18)
KPS RR, DCR, SI, AEs
Yue G 2014 [23] 86 48 42 38–69 86 Unavailable KPS RR, DCR, SI, AEs
Tu J 2014 [24] 90 41 49 45–70 90 Unavailable KPS RR, DCR, SI, AEs
Xu J 2014 [25] 70 43 27 44–70 70 >1000 ml KPS RR, DCR, SI, AEs
Wen X 2015 [26] 104 69 35 39–76 104 Unavailable KPS RR, DCR, SI, AEs
Hu X 2015 [27] 84 62 22 18–70 69 3 12 >1000 ml ECOG RR, DCR, SI, AEs
  1. N number of patients, MPE malignant pleural effusion, KPS karnofsky physical status score, RR response rate, DCR disease control rate, SI symptom improvement, AEs adverse effects, ECOG Eastern Cooperative Oncology Group (performance status)